Targeting the lincRNA00907/miRNA-942-5p/TAOK1 regulatory axis may hold promise for the development of novel therapeutic approaches for NASH treatment. The gene discussed is TAOK1; the disease is metabolic dysfunction-associated steatohepatitis.